Tvardi Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Imran Alibhai (CEO) and Dan Conn (CFO) issued standard Sarbanes-Oxley certifications for the Q2 2026 10-Q (quarter ended June 30, 2026, filed August 14, 2026). Both officers certified that the report contains no untrue material statements, that financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud involving management were disclosed.
Why this rating
Routine SOX certification with no red flags; standard quarterly filing requirement with no operational or financial changes disclosed herein.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.